within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10A_LipidModifyingAgentsPlain.C10AX07_MagnesiumPyridoxal5PhosphateGlutamate;

model MagnesiumPyridoxal5PhosphateGlutamate
  extends Pharmacolibrary.Drugs.ATC.C.C10AX07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C10AX07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Magnesium pyridoxal 5-phosphate glutamate is a combination medication containing a magnesium salt of pyridoxal 5-phosphate (an active form of vitamin B6) with glutamate. It has been used in some countries for the treatment of hyperlipidemia and to support cardiovascular health. It is not approved in the United States and has limited or no current widespread clinical use.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data in humans; the following are crude estimates based on closely related compounds (magnesium salts, B6 derivatives, glutamate) in healthy adults.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MagnesiumPyridoxal5PhosphateGlutamate;
